Administration of anti-CD137 mouse IgG2a, which preferentially depletes Treg cells, followed by either agonistic anti-CD137 mouse IgG1 or anti-PD-1 mAb augmented anti-tumor responses. Here, TNFRSF9 is linked to neoplasm.